Cerulean Pharma announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to CRLX101 for the treatment of ovarian cancer.
The company is studying the use of CRLX101 in combination with other treatments for relapsed ovarian cancer. Currently a Phase 2 trial of CRLX101 plus Avastin is enrolling patients and a Phase 1b trial of CRLX101 plus weekly paclitaxel in expected to start enrolling patients in the second quarter of 2015.
CRLX101 is a tumor-targeted nanoparticle-drug conjugate (NDC) designed to concentrate in tumors and slowly release camptothecin inside tumor cells.CRLX101 inhibits both topoisomerase 1 and hypoxia-inducible factor-1α (HIF-1α).
For more information visit CeruleanRx.com.